GAG Expertise

Emergent Technologies has acquired extensive experience and expertise in the evolving carbohydrate research development field over the past 5 years. Emergent Technologies currently manages and directs a unique group of glycosaminoglycan portfolio companies. Collectively Emergent Technologies and its portfolio companies have patents covering unique synthesis techniques for carbohydrate compounds such as heparin, chondroitin, hyaluronic acid and associated chimeric derivatives.

Emergent Technologies leverages this expertise across multiple industrial and general consumer application arenas and is positioned to serve as an international carbohydrate innovation clearinghouse.

Dr. Paul L. DeAngelis serves as the Chief Scientist of Heparinex. Dr. DeAngelis is a recognized leader in the glycobiology field and has been directly involved in commercializing technologies associated with heparin, chondroitin, and hyaluronic acid developed in his laboratories.

Carbohydrate Expertise: Paul L. DeAngelis has explored glycobiology throughout his career. As an undergraduate at Harvard (B.A. 1984), Dr. DeAngelis investigated the carbohydrate structures of polysaccharides from fungal pathogens that their plant hosts detected as "foreign" by creating and testing a series of synthetic structural mimics. As a graduate student at the University of California, Irvine (Ph.D. 1990), he elucidated unique details surrounding fertilization, such as defining the critical elements of egg surface polysaccharides and the essential residues of a sperm adhesive protein. As a postdoctoral researcher (1990-93) in the laboratory of Dr. Paul Weigel at the University of Texas Medical Branch, Galveston, Dr. DeAngelis identified the first hyaluronan synthase to be described from the human bacterial pathogen Group A Streptococcus. Currently, as a Professor at the University of Oklahoma Health Sciences Center in Oklahoma City, he directs a laboratory exploring various aspects of prokaryotic and eukaryotic polysaccharide biosynthesis. Discoveries from 1997 to 2003 include the identification of two more unique hyaluronan synthases and the first chondroitin and heparin synthase.

For more information visit the following link: http://w3.ouhsc.edu/biochem/DeAngelis.htm

Visit related companies Emergent Technologies, Inc., Hyalose L.L.C. and
Pure Protein, L.L.C.